Project Grant R43DK140050
Award Date
9/20/24
Completion Date
8/31/25
Dollars Obligated
$698K
Awardee
Vitakey Inc. (SUPCXTUWSCZ9)
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Washington, DC 20036, USA
Similar Awards
This $919,404 federal Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports the development of QR401, a first-in-class oral nanomedicine targeting antigen-presenting cells (APCs) for the treatment of inflammatory bowel disease (IBD). The funding will enable Qrono, Inc., a for-profit R&D company, to prepare and characterize enteric-coated...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $673,379 to Rise Therapeutics LLC to develop a novel synthetic biology-based cellular medicine for treating ulcerative colitis. The goal is to create an orally administered immunotherapy that can reduce gut inflammation, improve gastrointestinal mucosal barrier function, and restore the natural microbiome in...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $790,359 to the University of North Carolina at Chapel Hill to develop a targeted probiotic yeast therapy for treating inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. The project aims to design, characterize, and optimize a bioengineered Saccharomyces boulardii yeast that can...
This Project Grant award in the amount of $1,078,081 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The funding supports the development of a novel class of small molecule antagonists to the retinoic acid receptor-alpha (RAR) that can inhibit the gut migration of activated T cells, which is a promising therapeutic approach for inflammatory bowel disease...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $151,643 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Colorado-Denver. The grant supports research to develop proteolysis targeting chimeras (PROTACs) that can stabilize hypoxia-inducible factors (HIF) to enhance barrier formation and wound healing in inflammatory bowel disease models. The project aims to elucidate the...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $584,750 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to Foli Bio Inc. on September 17, 2024. The grant will fund the development and validation of Foli Bio's "EXFO-SEQ" technology, a non-invasive platform to analyze the exfoliome (RNA content exfoliated from intestinal cells) in stool samples. The goal is to generate insights into gene expression...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) provides $594,547 to the University of California, Davis to develop and characterize an orally delivered nanodrug designed to compensate for the shortage of specific microbial metabolite-regulated signaling in liver and colon cancer patients. The nanodrug, named PRORA, combines a histone deacetylase...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) provides $1,255,725 to the Icahn School of Medicine at Mount Sinai to develop manufacturing technologies and advance defined live biotherapeutic products (LBPs) for the treatment of recurrent Clostridioides difficile infection (rCDI) and ulcerative colitis. The key objectives are to: 1) develop a solid-state fermentation platform to enable rapid, scalable manufacturing of defined...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) will provide $184,572.00 to the University of Chicago to conduct research on characterizing the transmural nature of ulcerative colitis and its associated disease-related outcomes using intestinal ultrasound. The goal is to test the hypothesis that transmural structural alterations to the bowel wall in ulcerative colitis...
This Project Grant award, totaling $233,600.00 and spanning September 1, 2024 to June 30, 2027, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award supports high-throughput functional analyses of genetic drivers of inflammatory bowel disease (IBD), a debilitating condition characterized by chronic inflammation and erosion of intestinal functions. The...